MICHAEL D. KEPPEN, M.D.

Plain English
This study looked at a specific genetic mutation (V600E/K) in the blood of 149 patients with advanced melanoma who were not receiving targeted therapies. Researchers found that about half (55%) of patients with the mutation in their tumor also had the mutation detectable in their blood, and those with detectable mutations had a shorter time without disease progression (5.8 months compared to 12 months) and overall survival (9.2 months compared to 27.1 months). This is important because it shows that testing for this mutation in blood can help doctors assess how serious the patient's condition is. Who this helps: This helps patients with advanced melanoma and their doctors by identifying those at higher risk for more aggressive disease.

Plain English
This research studied a new treatment combining AT-101 with two common chemotherapy drugs, cisplatin and etoposide, for patients with advanced solid tumors, especially those with extensive-stage small cell lung cancer (ES-SCLC). The researchers found that the safe dose was determined to be AT-101 at 40 mg taken twice daily, along with specific doses of the other drugs, and they observed some signs of effectiveness in treating various cancers, including ES-SCLC. This is important because it suggests that this combination treatment could potentially improve outcomes for patients with these difficult-to-treat cancers. Who this helps: This helps patients with advanced solid tumors, particularly those with extensive-stage small cell lung cancer.

Plain English
This study looked at the effects of a drug called amonafide in patients with multiple myeloma who had already been treated without success. The researchers gave the drug to 16 patients at high doses, but found that while seven patients experienced significant side effects like low platelet and white blood cell counts, none of the patients showed any improvement in their condition. This is important because it highlights that amonafide is not effective for patients who have already been heavily treated for this cancer. Who this helps: This information helps doctors make better treatment decisions for patients with advanced multiple myeloma.

Plain English
This study focused on a 47-year-old man who had lung cancer and experienced fainting due to low blood pressure and low sodium in his blood. Researchers found that his levels of atrial natriuretic factor (ANF), a hormone linked to heart function, were three times higher than normal. This increase was likely due to cancer spreading to his heart, which put pressure on the heart chambers and heightened levels of this hormone, highlighting a serious connection between heart function and cancer progression. Who this helps: This information can benefit doctors treating patients with cancer to better manage heart-related symptoms.

Plain English
This study focused on a rare case of basal cell carcinoma, a type of skin cancer, that spread to other parts of the body in a patient with AIDS. The researchers found that patients with weakened immune systems, like those with AIDS, are at higher risk for both developing basal cell carcinoma and having it spread. This information is important because it highlights the need for careful monitoring and treatment options for people with AIDS to prevent and manage this type of cancer. Who this helps: This helps patients with AIDS and their doctors.

Plain English
Researchers studied upper gastrointestinal cancers in older adults, finding that while surgery is the best chance for curing these cancers, it also carries a high risk of death, and survival rates remain low. Current treatments like chemotherapy have limited success, but new approaches that combine surgery, radiation, and chemotherapy show promise, especially for esophageal cancer. The findings emphasize the need for better symptom management and innovative treatments to improve the quality of life for elderly patients facing these cancers. Who this helps: This helps elderly patients diagnosed with upper gastrointestinal cancers and their doctors.

Plain English
This study examined how effective the drug ketoconazole is at treating a fungal infection called systemic candidiasis in dogs that have low white blood cell counts (neutropenic). In tests, dogs treated with ketoconazole had no detectable fungal growth in their organs, while untreated dogs had high levels of infection. Specifically, none of the ketoconazole-treated dogs showed significant infection compared to high levels (up to 300,000 CFU) in the untreated group, highlighting that ketoconazole helps reduce serious infections in these vulnerable dogs. Who this helps: This research benefits veterinarians treating infected neutropenic dogs, especially those undergoing procedures like bone marrow transplants.